Physician profile
Christopher Ignatz
NPI 1538655501
$708.45
in general payments reported to CMS, 2019-2025
14 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.54 · 2020: $12.78 · 2022: $80.92 · 2023: $132 · 2024: $295 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.22 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $152.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $113.40 | 2024 | Dupixent |
| Harmony Biosciences LLC | $106.59 | 2023-2024 | Wakix |
| Novo Nordisk INC | $69.54 | 2019 | |
| Mylan Specialty L.P. | $59.41 | 2022-2024 | Yupelri |
| Glaxosmithkline, LLC. | $37.41 | 2022-2024 | Trelegy Ellipta |
| Insmed, INC. | $32.93 | 2025 | Arikayce |
| Mallinckrodt Hospital Products INC. | $30.34 | 2022 | |
| Ambu INC. | $24.14 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.91 | 2023 | |
| Merck Sharp & Dohme LLC | $17.77 | 2025 | Recarbrio, Zerbaxa |
| Philips North America LLC | $15.89 | 2022 | |
| Axsome Therapeutics, INC. | $13.73 | 2023 | Sunosi |
| Allergan, INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ignatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.